Concepedia

Robert B. Kammer

RB

10

Publications

868

Citations

10

H-Index

1974

Active since

Affiliations

Eli Lilly (United States)(Current)

Robert B. Kammer is an author at Eli Lilly (United States) specializing in medicine, clinical microbiology, and drug resistance.

Top concepts

MedicineClinical MicrobiologyHealthDrug ResistanceAntibioticsPharmacologyPharmacotherapyInfection ControlMedicinal ChemistryAntimicrobial Resistance

Publications per year

1974–2001

10

Publications

10

Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections

Anthony W. Chow, Caroline B. Hall, Jerome O. Klein et al. · Clinical Infectious Diseases · 1992 · 190 citations · Full text

Antibiotic Adjuvant, Antimicrobial Chemotherapy, Bacterial Pathogens +17

Aspergillus species endocarditis

Robert B. Kammer, John P. Utz · The American Journal of Medicine · 1974 · 146 citations

Infective Endocarditis, Clinical Mycology, Microbiology +2

QS-21: a water-soluble triterpene glycoside adjuvant

Charlotte R. Kensil, Robert B. Kammer · Expert Opinion on Investigational Drugs · 1998 · 145 citations

Pharmaceutical Science, Glycobiology, Immunology +18

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21

Douglas C. Waite, Eric Jacobson, Francis A. Ennis et al. · Vaccine · 2001 · 130 citations

Therapeutic Drug Monitoring, Medicinal Chemistry, Medicine +4

Hematologic Complications Associated with β-Lactam Antibiotics

Nils U. Bang, Robert B. Kammer · Clinical Infectious Diseases · 1983 · 90 citations

Rows per page

1–5 of 10